 CARMIEL, Israel and BOSTON, April 28, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American:PLX TASE:PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group Chiesi Group, today announced that they received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA regarding the Biologics License Application BLA seeking accelerated approval of pegunigalsidase alfa PRX102 for the proposed treatment of adult patients with Fabry disease. 